Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | DPP3 | Q9NY33 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7332314 | 1.00 | ACE (0.72) | ACECYP2C19DPP3BCHENTSR2 | |
| SCHEMBL7332773 | 0.93 | ACE (0.66) | ACECYP2C19DPP3BCHENTSR2 | |
| SCHEMBL683545 | 0.91 | ACE (0.60) | ACECYP2C19DPP3BCHELMNA | |
| SCHEMBL11256646 | 0.89 | ACE (0.56) | ACECYP2C19DPP3BCHEDPP4 | |
| SCHEMBL10781418 | 0.86 | ACE (0.64) | ACECYP2C19DPP3BCHENTSR2 | |
| SCHEMBL7326949 | 0.86 | ACE (0.79) | ACELMNA | |
| SCHEMBL7321737 | 0.85 | ACE (0.70) | ACECYP2C19DPP3BCHELMNA | |
| SCHEMBL11254282 | 0.85 | ACE (0.51) | ACECYP2C19DPP3BCHELMNA | |
| Lisinopril Anhydrous SCHEMBL24062681 | 0.84 | ACE (1.00) | ACELMNA | |
| Lisinopril Anhydrous SCHEMBL15680 | 0.84 | ACE (1.00) | ACELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | ACE 4514/4885CYP2C19 4864/4885DPP3 1265/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ACE 6/4885CYP2C19 4575/4885DPP3 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.